Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841045 | 0.77 | IDO1 (0.37) | IDO1TDO2P2RX7ALDH1A1CYP1A2 | |
| SCHEMBL8911591 | 0.76 | P2RX7 (0.47) | IDO1TDO2P2RX7ALDH1A1OPRL1 | |
| SCHEMBL1747971 | 0.76 | IDO1 (0.36) | IDO1TDO2CA1CA2CA5A | |
| SCHEMBL263736 | 0.76 | IDO1 (0.36) | IDO1TDO2CA1CA2CA5A | |
| SCHEMBL305225 | 0.72 | IDO1 (0.43) | IDO1TDO2CA1CA2HTT | |
| SCHEMBL15973428 | 0.71 | HTT (0.42) | IDO1TDO2CA1CA2HTT | |
| Water SCHEMBL17537053 | 0.71 | ALDH1A1 (0.59) | HTTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29498705 | 0.70 | IDO1 (0.42) | IDO1TDO2CA1CA2CA5A | |
| SCHEMBL183025 | 0.70 | IDO1 (0.42) | IDO1TDO2CA1CA2CA5A | |
| SCHEMBL28865878 | 0.70 | CES2 (0.41) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | IDO1 99/4885TDO2 681/4885CA1 2256/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | IDO1 70/4885TDO2 133/4885CA1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.